First Trust Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

First Trust Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,176	Closed	-$180K	–	2530
2020 Q2	$180K	Sell	12,176 -21,720	-64%	-$321K	﹤0.01%	2278
2020 Q1	$458K	Buy	+33,896	New	+$643K	﹤0.01%	1979

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

First Trust Advisors's AERI Position: Q3 2020 in Review

First Trust Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2020, closing a stake of 12,176 shares — an estimated $180K sold.

First Trust Advisors first reported a position in AERI in Q1 2020 and held it in 2 quarters. The position peaked at $458K in Q1 2020. 148 funds tracked by Wall St. Rank hold AERI as of Q3 2020.

First Trust Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
First Trust Advisors sold 12,176 Aerie Pharmaceuticals shares in Q3 2020, an estimated $180K.
First Trust Advisors first reported a position in Aerie Pharmaceuticals in Q1 2020 and held it in 2 quarters.
First Trust Advisors's Aerie Pharmaceuticals position peaked at $458K in Q1 2020.
148 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2020.

Based on First Trust Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.